Emergent Biosolutions (NYSE:EBS) SVP Sells 3,000 Shares

Emergent Biosolutions Inc. (NYSE:EBS) SVP Paul Anthony Williams sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the sale, the senior vice president directly owned 159,098 shares in the company, valued at approximately $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Price Performance

Shares of NYSE:EBS traded down $0.12 during trading on Thursday, hitting $8.16. 335,640 shares of the company’s stock were exchanged, compared to its average volume of 880,742. The business’s 50-day simple moving average is $8.36 and its 200 day simple moving average is $9.67. The company has a market cap of $421.11 million, a price-to-earnings ratio of -29.12 and a beta of 2.34. Emergent Biosolutions Inc. has a 52-week low of $5.61 and a 52-week high of $14.06. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.29 and a quick ratio of 2.08.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.46. The company had revenue of $156.10 million for the quarter, compared to analysts’ expectations of $145.00 million. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on EBS shares. HC Wainwright dropped their price target on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Wall Street Zen cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Weiss Ratings downgraded Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Finally, UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Emergent Biosolutions has a consensus rating of “Hold” and a consensus target price of $12.00.

Institutional Investors Weigh In On Emergent Biosolutions

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EBS. Torren Management LLC bought a new position in shares of Emergent Biosolutions during the 4th quarter valued at approximately $37,000. CANADA LIFE ASSURANCE Co bought a new position in Emergent Biosolutions during the fourth quarter valued at $45,000. Legal & General Group Plc bought a new position in Emergent Biosolutions during the second quarter valued at $31,000. Farther Finance Advisors LLC raised its stake in shares of Emergent Biosolutions by 361.3% in the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 4,827 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Emergent Biosolutions in the second quarter valued at $53,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.